How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?

References

• Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44–e122
   PubMed Web of Science ®Google Scholar
• Manolis AS, Manolis TA, Papadimitriou P, Koulouris S, Melita H. Combined antiplatelet therapy: Still a sweeping combination in cardiology. Cardiovasc Hematol Agents Med Chem 2013;11:136–167
   PubMedGoogle Scholar
• Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: Observations from the clopidogrel in unstable angina to prevent recurrent events (cure) study. Circulation 2003;108:1682–1687
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366:1607–1621
   PubMed Web of Science ®Google Scholar
• Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073–3076
   PubMed Web of Science ®Google Scholar
• Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005;353:2373–2383
   PubMed Web of Science ®Google Scholar
• Patrono C. Antiplatelet therapy. In: Michelson AD, editor. Platelets. Academic Press: New York; 2012. pp 1337–1348
   Google Scholar
• Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK. P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 2012;33:143–153
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Mechanisms of variability in antiplatelet agents response. Thromb Res 2012;130:S27–S28
   PubMed Web of Science ®Google Scholar
• Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, Peterfy H, Kiss RG, Edes I, Muszbek L. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 2014;133:811–816
   PubMed Web of Science ®Google Scholar
• Ofosu FA. Appropriate assessment of the functional consequences of platelet cyclooxygenase-1 inhibition by aspirin in vivo. Thromb Res 2014;133:697–698
   PubMed Web of Science ®Google Scholar
• Kovacs EG, Katona E, Bereczky Z, Homorodi N, Balogh L, Toth E, Peterfy H, Kiss RG, Edes I, Muszbek L. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin: The lack of aspirin resistance among healthy individuals. Thromb Res 2014;131:320–324
   Web of Science ®Google Scholar
• Floyd CN, Ferro A. Mechanisms of aspirin resistance. Pharmacol Ther 2014;141:69–78
   PubMed Web of Science ®Google Scholar
• Shantsila E, Lip GY. ‘Aspirin resistance’ or treatment non-compliance: Which is to blame for cardiovascular complications? J Transl Med 2008;6:47
   PubMed Web of Science ®Google Scholar
• Cattaneo M. The clinical relevance of response variability to antiplatelet therapy. Hematology Am Soc Hematol Educ Program 2011;2011:70–75
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Response variability to clopidogrel: Is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost 2011;10:327–336
   Web of Science ®Google Scholar
• Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–2273
   PubMed Web of Science ®Google Scholar
• Mallouk N, Labruyere C, Reny JL, Chapelle C, Piot M, Fontana P, Gris JC, Delavenne X, Mismetti P, Laporte S. Prevalence of poor biological response to clopidogrel: A systematic review. Thromb Haemost 2012;107:494–506
   PubMed Web of Science ®Google Scholar
• Ait-Mokhtar O, Bonello L, Benamara S, Paganelli F. High on treatment platelet reactivity. Heart Lung Circ 2012;21:12–21
   PubMed Web of Science ®Google Scholar
• Gremmel T, Panzer S. Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel. Thromb Haemost 2011;106:211–218
   PubMed Web of Science ®Google Scholar
• Sibbing D, Orban M, Massberg S. Potent P2Y12 receptor inhibitors in patients with acute coronary syndrome: Agents, indications, issues to consider in clinical practice. Hamostaseologie 2013;33:9–15
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Clopidogrel response variability and the advent of personalised antiplatelet therapy: A bench to bedside journey. Thromb Haemost 2011;106:265–271
   PubMed Web of Science ®Google Scholar
• Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919–933
   PubMed Web of Science ®Google Scholar
• Aradi D, Storey RF, Komocsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35:209–215
   PubMed Web of Science ®Google Scholar
• Aradi D, Sibbing D, Bonello L. Current evidence for monitoring platelet reactivity in acute coronary syndrome: A plea for individualized antiplatelet treatment. Int J Cardiol 2013;167:1794–1797
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5:230–237
   PubMed Web of Science ®Google Scholar
• Bagoly Z, Sarkady F, Magyar T, Kappelmayer J, Pongracz E, Csiba L, Muszbek L. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy. PLoS One 2013;8:e69417
   PubMed Web of Science ®Google Scholar
• Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85–92
   PubMed Web of Science ®Google Scholar
• Horowitz GL, Altaie S, Boyd JC, Ceriotti F, Garg U, Horn P, Pesce A, Sine HE, Zakowski J. Defining, establishing, and verifying reference intervals in the clinical laboratory: Approved guideline. 3rd edition. Clinical and Laboratory Standards Institute Document C28-A3, vol. 28; 2008
   Google Scholar
• Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, Pettinella C, Recchiuti A, Ferrante E, Ciabattoni G, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: Implications for aspirin “Resistance”. J Am Coll Cardiol 2009;53:667–677
   PubMed Web of Science ®Google Scholar
• Kasmeridis C, Apostolakis S, Lip GY. Aspirin and aspirin resistance in coronary artery disease. Curr Opin Pharmacol 2013;13:242–250
   PubMed Web of Science ®Google Scholar
• Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595–3603
   PubMed Web of Science ®Google Scholar
• Paikin JS, Hirsh J, Ginsberg JS, Weitz JI, Chan NC, Whitlock RP, Pare G, Johnston M, Eikelboom JW. Multiple daily doses of ASA overcome reduced platelet response to once-daily ASA after CABG: A pilot randomized controlled trial. J Thromb Haemost 2015;13:448–456
   PubMed Web of Science ®Google Scholar
• Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002;99:193–198
   PubMed Web of Science ®Google Scholar
• Shankar H, Garcia A, Prabhakar J, Kim S, Kunapuli SP. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1/2 activation. J Thromb Haemost 2006;4:638–647
   PubMed Web of Science ®Google Scholar